PAPYRUS

Papyrus Therapeutics is a preclinical-stage biopharmaceutical company pioneering a novel approach to cancer treatment through tumor suppressor replacement therapy. The company's proprietary OP-TSR (Onco-Primal Tumor Suppressor Replacement) platform focuses on restoring the function of extracellular tumor suppressors that are often lost or silenced in cancer cells. By utilizing recombinant versions of these naturally occurring proteins, Papyrus aims to inhibit tumor growth and overcome resistance to existing therapies. Their lead programs target high-unmet-need indications in oncology, including solid tumors such as breast and lung cancer.